Business Wire

12 Major Verification Trends in 2026: Regula on the Birth of a New Digital Identity

20.11.2025 14:00:00 CET | Business Wire | Press Release

Share

How we verify is changing — and so is who and what we verify. Are we dealing with real people, fraudsters, or machines acting on their behalf? A new Regula report on 12 identity verification trendsexamines how these shifts are forcing businesses to rebuild their verification processes to stay ahead of fraud, comply with regulations, and regain eroding customer confidence.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251120373343/en/

Identity is leaving the human domain: Regula’s forecast illustrates the emerging need to verify systems, autonomous agents, and machine customers.

The new face of fraud

The identity threat landscape has entered a new industrial phase, defined by three structural shifts:

  • Machine identity. Identity verification (IDV) is no longer limited to people. It now extends to autonomous systems acting on their behalf — AI agents that can open accounts, submit documents, and bypass checks on their own.
  • Fraud for hire. Deepfake and impersonation fraud have gone mainstream. Complete “persona kits” — synthetic faces, voices, and backstories — are sold off the shelf. Identity forgery has scaled from a skill to a service.
  • Coordinated AI attacks. Networks of AI systems work together, brute-forcing verification systems. One model fabricates documents, another impersonates a person in live video, and a third learns from each failed attempt.

As the line between human and machine identities fades, the purpose of verification is shifting. As Ihar Kliashchou, Chief Technology Officer at Regula puts it, “Trust now begins at the source, not at the checkpoint. The traceable origin of a document, image, or signal is becoming as important as the content itself.”

In essence, the fight against fraud is shifting from pattern recognition to origin verification: from asking just one question, “Is this real?” to adding context like “Where did this come from?”

The trust stack

Verification is evolving from a process that proves compliance to one that enforces accountability. As algorithms make more decisions, businesses must ensure that their systems are transparent, auditable, and explainable. Compliance is no longer a checklist — it’s an operating standard.

Unified verification systems. To meet these demands, organizations are consolidating fragmented tools into unified end-to-end IDV platforms that orchestrate document checks, biometrics, and screening under a single policy layer. “Disconnected verification tools are no longer a technical issue — they’re a compliance risk,” notes Ihar Kliashchou.

New types of customers. Identity is expanding beyond people to include machines, algorithms, and self-authenticating systems that act independently. The rise of these machine customers — capable of signing, transacting, or negotiating on their own — requires new frameworks to trace every digital actor back to a responsible entity.

Just like with programmable money, the same logic applies to finance. Every digital payment is now a verification event itself: it carries its own proof of who, what, and why.

Preparing for post-quantum trust. The shift to post-quantum cryptography — encryption built to resist quantum computer hacks — will reshape how authenticity and credentials are secured. Organizations that prepare early (e.g., by mapping dependencies and adopting agile, quantum-resistant frameworks) will treat this change as an upgrade of digital trust, not an emergency fix.

“The future of identity isn’t human or machine — it’s both, verified together,” says Henry Patishman, Executive Vice President for Identity Verification Solutions at Regula.

What it means for businesses

Identity verification is becoming a competitive edge, not a checkbox. As AI blurs the line between human and machine identity, companies need to verify faster and with greater transparency to limit fraud, meet regulations, and maintain trust. For sectors from banking to travel, stronger verification cuts fraud losses, speeds up onboarding, and keeps customers confident.

Businesses that treat identity as core infrastructure — not an add-on — will be better prepared for the next wave of digital risk and regulation.

Read the full report

Discover the complete IDV trends envisioned in Regula’s new report, 12 Trends Reshaping How We Verify, Trust, and Protect, which is available on the Regula website. The report dives deeper into the challenges and opportunities that will define identity verification in 2026 and beyond.

About Regula

Regula is a global developer of forensic devices and identity verification solutions. With our 30+ years of experience in forensic research and the most comprehensive library of document templates in the world, we create breakthrough technologies for document and biometric verification. Our hardware and software solutions allow over 1,000 organizations and 80 border control authorities globally to provide top-notch client service without compromising safety, security, or speed. Regula has been recognized in the 2025 Gartner® Magic Quadrant™ for Identity Verification.

Learn more at www.regulaforensics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251120373343/en/

Contacts

Kristina – ks@regula.us

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye